EUVIMEDEUVIMED entdecken
Crossref

A Novel Signature Based on m 6 A Regulator‐Mediated Genes Along Glycolytic Pathway Predicts Prognosis and Immunotherapy Responses of Gastric Cancer Patients

Duanrui Liu, Binbin Li, Mingyue Yang, Yuanxin Xing, Yunyun Liu, Mingjie Yuan, Fen Liu, Yufei Wu, Xiaoli Ma, Yanfei Jia, Yunshan Wang, Mingyu Ji und 1 weitere

Advanced Biology · 2024

DOI: 10.1002/adbi.202300534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Biology, 2024. Verfasst von Duanrui Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Basic Medicine, Jinan Central Hospital, Shandong University, Jinan, 250013, P. R. China. Hauptthemen laut MEDLINE: Stomach Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Academic Promotion Program of Shandong First Medical University, Shandong Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N6‐methyladenosine (m 6 A) modification is involved in many aspects of gastric cancer (GC). Moreover, m6A and glycolysis‐related genes (GRGs) play important roles in immunotherapeutic and prognostic implication of GC. However, GRGs involved in m6A regulation have never been analyzed comprehensively in GC. Herein, the study aims to identify and validate a novel signature based on m6A‐related GRGs in GC patients. Therefore, a m 6 A‐related GRGs signature is established, which can predict the survival of patients with GC and remain an independent prognostic factor in multivariate analyses. Clinical significance of the model is well validated in internal cohort and independent validation cohort. In addition, the expression levels of risk model‐related GRGs in clinical samples are validated. Consistent with the database results, all model genes are up‐regulated in expression except DCN. After regrouping the patients based on this risk model, the study can effectively distinguish between them in respect to immune‐cell infiltration microenvironment and immunotherapeutic response. Additionally, candidate drugs targeting risk model‐related GRGs are confirmed. Finally, a nomogram combining risk scores and clinical parameters is created, and calibration plots show that the nomogram can accurately predict survival. This risk model can serve as a reliable assessment tool for predicting prognosis and immunotherapeutic responses in GC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsHumansPrognosisGenes, RegulatorNomogramsImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

gastric cancerglycolysisimmunotherapym6Aprognosis

Autor:innen und Institutionen

  • Research Center of Basic Medicine, Jinan Central Hospital, Shandong University, Jinan, 250013, P. R. China.
  • Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, P. R. China.
  • Research Center of Basic Medicine, Jinan Central Hospital, Shandong First Medical University, Jinan, 250013, P. R. China.
  • Department of Clinical Laboratory, Weihai Municipal Hospital, Weihai, 264299, P. R. China.
  • Medical Research & Laboratory Diagnostic Center, Jinan Central Hospital, Shandong First Medical University, Jinan, 250013, P. R. China.
  • Department of Clinical Laboratory, Linyi Central Hospital, Linyi, 276400, P. R. China.

ORCID-Profile: Jingyu Zhu

Förderung

  • National Natural Science Foundation of China
  • Academic Promotion Program of Shandong First Medical University
  • Shandong Provincial Natural Science Foundation of China

Zitieren

APA

Liu, D., Li, B., Yang, M., Xing, Y., Liu, Y., Yuan, M., Liu, F., Wu, Y., Ma, X., Jia, Y., Wang, Y., Ji, M., & Zhu, J. (2024). A Novel Signature Based on m 6 A Regulator‐Mediated Genes Along Glycolytic Pathway Predicts Prognosis and Immunotherapy Responses of Gastric Cancer Patients. Advanced Biology. https://doi.org/10.1002/adbi.202300534

Vancouver

Liu D, Li B, Yang M, Xing Y, Liu Y, Yuan M, et al. A Novel Signature Based on m 6 A Regulator‐Mediated Genes Along Glycolytic Pathway Predicts Prognosis and Immunotherapy Responses of Gastric Cancer Patients. Advanced Biology. 2024. doi:10.1002/adbi.202300534

BibTeX
@article{Liu2024,
  author = {Liu, Duanrui and Li, Binbin and Yang, Mingyue and Xing, Yuanxin and Liu, Yunyun and Yuan, Mingjie and Liu, Fen and Wu, Yufei and Ma, Xiaoli and Jia, Yanfei and Wang, Yunshan and Ji, Mingyu and Zhu, Jingyu},
  title = {A Novel Signature Based on m 6 A Regulator‐Mediated Genes Along Glycolytic Pathway Predicts Prognosis and Immunotherapy Responses of Gastric Cancer Patients},
  journal = {Advanced Biology},
  year = {2024},
  doi = {10.1002/adbi.202300534}
}
Kostenlos starten →